These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30388142)

  • 1. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
    Fukunaga T; Fujita Y; Kishima H; Yamashita T
    PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
    Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
    Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
    Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
    Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
    Glowacka WK; Jain H; Okura M; Maimaitiming A; Mamatjan Y; Nejad R; Farooq H; Taylor MD; Aldape K; Kongkham P
    Acta Neuropathol; 2018 Apr; 135(4):617-634. PubMed ID: 29428975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
    de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
    Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
    Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
    Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis of non-coding transcripts reveals the prognostic onco-lncRNA HOXA10-AS in gliomas.
    Isaev K; Jiang L; Wu S; Lee CA; Watters V; Fort V; Tsai R; Coutinho FJ; Hussein SMI; Zhang J; Wu J; Dirks PB; Schramek D; Reimand J
    Cell Rep; 2021 Oct; 37(3):109873. PubMed ID: 34686327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
    Müller T; Gessi M; Waha A; Isselstein LJ; Luxen D; Freihoff D; Freihoff J; Becker A; Simon M; Hammes J; Denkhaus D; zur Mühlen A; Pietsch T; Waha A
    Am J Pathol; 2012 Aug; 181(2):675-83. PubMed ID: 22688054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
    Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
    Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
    Mo H; Magaki S; Deisch JK; Raghavan R
    J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
    PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
    Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
    J Neurosurg; 2020 Jan; 132(1):168-179. PubMed ID: 30641835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.